zuclopenthixol

Ligand id: 7559

Name: zuclopenthixol

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: zuclopenthixol

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 52.01
Molecular weight 400.14
XLogP 3.89
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used to treat schizophrenia and acute mania. There is no information regarding approval for clinical use of this drug on the US FDA or European Medicines Agency (EMA) websites. Individual national approval agencies may have granted marketing authorisation. See Drugs.com for a list of countries where this drug may be in use. In the UK three salt formulations of zuclopenthixol are approved; acetate (PubChem CID 6436640, injectable form), decanoate (PubChem CID 6450333, injectable form) and dihydrochloride (PubChem CID 6433208), tablet form).
Mechanism Of Action and Pharmacodynamic Effects
Zuclopenthixol is an antagonist of the dopamine D1 and D2 receptor subtypes. Drug treatment induces sedation and improves psychotic symptoms.
External links